Last reviewed · How we verify
"Raylis"
Raylis is a selective androgen receptor modulator (SARM) that acts as a partial agonist to selectively target androgen receptors in muscle and bone, promoting anabolic effects without the side effects associated with full agonists.
Raylis is a selective androgen receptor modulator (SARM) that acts as a partial agonist to selectively target androgen receptors in muscle and bone, promoting anabolic effects without the side effects associated with full agonists. Used for Hypogonadism, Muscle wasting diseases.
At a glance
| Generic name | "Raylis" |
|---|---|
| Sponsor | The Clinic of Men's Health and Couple Longevity, Russia |
| Drug class | Selective androgen receptor modulator (SARM) |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Hypogonadism, Muscle wasting diseases |
| Phase | Phase 3 |
Mechanism of action
By selectively targeting androgen receptors, Raylis aims to increase muscle mass and bone density while minimizing the risk of prostate issues and other side effects associated with full androgen receptor agonists. This mechanism of action is thought to be beneficial for conditions such as hypogonadism and muscle wasting diseases.
Approved indications
- Hypogonadism
- Muscle wasting diseases
Common side effects
- Elevated liver enzymes
- Hypertension
- Acne
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- "Raylis" CI brief — competitive landscape report
- "Raylis" updates RSS · CI watch RSS
- The Clinic of Men's Health and Couple Longevity, Russia portfolio CI